PDF(Pubmed)
Abstract：
Veterinary oncology has experienced significant evolution over the last few decades, with chemotherapy being currently applied to several neoplasms with therapeutic success. Traditionally, chemotherapy protocols are based on classic cytostatic drugs under the concept of maximum tolerated dose (MTD), which has been associated with a greater risk of toxicity and resistance. Thus, new therapeutic alternatives have emerged, such as metronomic chemotherapy (MC), introducing a new paradigm in cancer treatment. MC consists of administering low doses of chemotherapy drugs continuously over a long period of time, modulating the tumour microenvironment (TME) due to the combination of cytotoxic, antiangiogenic and immunomodulatory effects. This multi-targeted therapy has been described as a treatment option in several canine and feline cancers since 2007, with positive results already published in the literature, particularly in mammary carcinomas and soft tissue sarcomas in dogs. The aim of this review article is to describe the current knowledge about the use of MC in small animal oncology, with emphasis on its mechanisms of action, the most commonly used drugs and clinical outcome.
摘要：
在过去的几十年里，兽医肿瘤学经历了重大的发展，化疗目前应用于几种肿瘤，治疗成功。传统上,化疗方案基于最大耐受剂量（MTD）概念下的经典细胞抑制药物，这与更大的毒性和耐药性风险有关。因此，出现了新的治疗替代方案，如节拍化疗（MC），引入癌症治疗的新模式。MC包括长时间连续施用低剂量的化疗药物，由于细胞毒性的组合，调节肿瘤微环境（TME），抗血管生成和免疫调节作用。自2007年以来，这种多靶向治疗已被描述为几种犬科动物和猫科动物癌症的治疗选择，并已在文献中发表了积极的结果。特别是在狗的乳腺癌和软组织肉瘤中。这篇综述文章的目的是描述有关MC在小动物肿瘤学中使用的最新知识，强调其行动机制，最常用的药物和临床结果。
